Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

Also called NCT01516151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 289 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01516151
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01516151. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
Condition
Hypertriglyceridemia
Intervention (Dietary supplement)
CaPre™
Intervention (Dietary supplement)
CaPre™
Intervention (Dietary supplement)
CaPre™
Intervention (Drug)
Lipid Lowering Medication
Intervention (Dietary supplement)
CaPre™
Lead sponsor
Grace Therapeutics Inc. (class: industry)
Collaborator
JSS Medical Research Inc. (class: industry)

Record details

Record id
cardio:ct-nct01516151
Content hash
ddc91c3a00048d23a413e26e54d7c6b453f7401bbd6127710dbc1d832c15d32a